Literature DB >> 15287081

A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.

Patrick Royston1, Willi Sauerbrei.   

Abstract

We consider modelling interaction between a categoric covariate T and a continuous covariate Z in a regression model. Here T represents the two treatment arms in a parallel-group clinical trial and Z is a prognostic factor which may influence response to treatment (known as a predictive factor). Generalization to more than two treatments is straightforward. The usual approach to analysis is to categorize Z into groups according to cutpoint(s) and to analyse the interaction in a model with main effects and multiplicative terms. The cutpoint approach raises several well-known and difficult issues for the analyst. We propose an alternative approach based on fractional polynomial (FP) modelling of Z in all patients and at each level of T. Other prognostic variables can also be incorporated by first constructing a multivariable adjustment model which may contain binary covariates and FP transformations of continuous covariates other than Z. The main step involves FP modelling of Z and testing equality of regression coefficients between treatment groups in an interaction model adjusted for other covariates. Extensive experience suggests that a two-term fractional polynomial (FP2) function may describe the effect of a prognostic factor on a survival outcome quite well. In a controlled trial, this FP2 function describes the prognostic effect averaged over the treatment groups. We refit this function in each treatment group to see if there are substantial differences between groups. Allowing different parameter values for the chosen FP2 function is flexible enough to detect such differences. Within the same algorithm we can also deal with the conceptually different cases of a predefined hypothesis of interaction or searching for interactions. We demonstrate the ability of the approach to detect and display treatment/covariate interactions in two examples from controlled trials in cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15287081     DOI: 10.1002/sim.1815

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  81 in total

1.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  Analysis of randomized comparative clinical trial data for personalized treatment selections.

Authors:  Tianxi Cai; Lu Tian; Peggy H Wong; L J Wei
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

4.  Patient-centered yes/no prognosis using learning machines.

Authors:  I R König; J D Malley; S Pajevic; C Weimar; H-C Diener; A Ziegler
Journal:  Int J Data Min Bioinform       Date:  2008       Impact factor: 0.667

5.  The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterol.

Authors:  Nilesh J Samani; Peter S Braund; Jeanette Erdmann; Anika Götz; Maciej Tomaszewski; Patrick Linsel-Nitschke; Cother Hajat; Massimo Mangino; Christian Hengstenberg; Klaus Stark; Andreas Ziegler; Mark Caulfield; Paul R Burton; Heribert Schunkert; Martin D Tobin
Journal:  J Mol Med (Berl)       Date:  2008-07-23       Impact factor: 4.599

Review 6.  Linear, nonlinear or categorical: how to treat complex associations in regression analyses? Polynomial transformations and fractional polynomials.

Authors:  Carsten Oliver Schmidt; Till Ittermann; Andrea Schulz; Hans J Grabe; Sebastian E Baumeister
Journal:  Int J Public Health       Date:  2012-05-09       Impact factor: 3.380

7.  Preoperative inflammation increases the risk of infection after elective colorectal surgery: results from a prospective cohort.

Authors:  Luigi De Magistris; Brice Paquette; David Orry; Olivier Facy; Giovanni Di Giacomo; Patrick Rat; Christine Binquet; Pablo Ortega-Deballon
Journal:  Int J Colorectal Dis       Date:  2016-06-29       Impact factor: 2.571

8.  Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms.

Authors:  O Naggara; J Raymond; F Guilbert; D Roy; A Weill; D G Altman
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

9.  Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Authors:  Martin E Gore; Clare L Griffin; Barry Hancock; Poulam M Patel; Lynda Pyle; Michael Aitchison; Nicholas James; Roderick T D Oliver; Jozef Mardiak; Tahera Hussain; Richard Sylvester; Mahesh K B Parmar; Patrick Royston; Peter F A Mulders
Journal:  Lancet       Date:  2010-02-10       Impact factor: 79.321

10.  Physiologic field triage criteria for identifying seriously injured older adults.

Authors:  Craig D Newgard; Derek Richardson; James F Holmes; Thomas D Rea; Renee Y Hsia; N Clay Mann; Kristan Staudenmayer; Erik D Barton; Eileen M Bulger; Jason S Haukoos
Journal:  Prehosp Emerg Care       Date:  2014-06-16       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.